Drug Fix: Regeneron’s COVID Monoclonal Deal, New FDA Advisor, Project Optimus In Cancer Combos

Pink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron’s deal with the US government to develop a COVID-19 monoclonal antibody (:34), US FDA Commissioner Robert Califf hiring a new senior advisor (12:10), and optimizing dosing in cancer combination therapies (21:21). More On These Topics From The Pink Sheet Price Caps In Regeneron’s COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie: https://pink.citeline.com/PS148843/Price-Caps-In-Regenerons-COVID-Monoclonal-Deal-With-HHS-Not-A-Precedent-But-Enough-For-Bernie Califf Hires New US FDA Senior Advisor, But Duties Seem Vague: https://pink.citeline.com/PS148848/Califf-Hires-New-US-FDA-Senior-Advisor-But-Duties-Seem-Vague Project Optimus Is Coming To Cancer Combination Therapy Development: https://pink.citeline.com/PS148841/Project-Optimus-Is-Coming-To-Cancer-Combination-Therapy-Development